Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Macrogenics (MGNX) Invested Capital (2016 - 2025)

Macrogenics (MGNX) has disclosed Invested Capital for 14 consecutive years, with $55.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital fell 52.1% to $55.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $55.6 million, a 52.1% decrease, with the full-year FY2025 number at $55.6 million, down 52.1% from a year prior.
  • Invested Capital was $55.6 million for Q4 2025 at Macrogenics, up from $46.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $319.0 million in Q2 2021 to a low of $46.6 million in Q2 2025.
  • A 5-year average of $158.6 million and a median of $142.2 million in 2022 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: tumbled 57.81% in 2022, then skyrocketed 57.76% in 2023.
  • Macrogenics' Invested Capital stood at $239.6 million in 2021, then tumbled by 40.73% to $142.0 million in 2022, then rose by 7.46% to $152.6 million in 2023, then dropped by 23.95% to $116.1 million in 2024, then crashed by 52.1% to $55.6 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Invested Capital are $55.6 million (Q4 2025), $46.6 million (Q2 2025), and $116.1 million (Q4 2024).